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Heart failure (HF) is an intriguing model of chronic disease. It starts as an organ disorder
developing, in its progression, into a systemic disease in which the dysfunction of other
organs plays a relevant clinical and prognostic impact. Furthermore, continuous activation
of systemic pathways plays a role in disease progression, switching their effect from
protective to harmful. In this combination of organ dysfunction and systemic
derangement, thyroid hormone (TH) have an important regulative impact from
cardiovascular to systemic level and from molecular/cellular processes to clinical setting.
Whether it is accepted to include TH and thyroid stimulating hormone assessment in the
clinical HF course, the next challenge will be to ascertain the benefit of TH replacement
therapy in HF patients, taking into consideration the type of hormone to administer,
dosage and treatment schedule.
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The thyroid hormone (TH) system regulates
several organ-specific functions directly through
genomic and non-genomic actions and indi-
rectly by modulating hormonal and tissue
molecular pathways. Further toward the inter-
action of TH with systemic pathways, that is
hormones, inflammatory central and autonomic
nervous system pathways facilitate the liaison
and the integration of the actions among differ-
ent organs and systems. A proof of this is the
physiological relevance of TH system in the
processes of growth, cell differentiation and
protection and in the pathophysiological and
clinical impact of an altered TH profile in dif-
ferent disease states. Relaxation and contractile
properties of the myocardium are both inter-
fered by TH through regulation of the calcium
handling and myosin heavy chain (MHC)
expression, respectively. Also the effects of TH
on the cardiac dynamics are indirectly mediated
by TH-induced reduction in peripheral vascular
resistance that improves cardiac loading condi-
tions and ventricle–arterial coupling, thus lead-
ing to a more favorable balance for the heart
work. Beyond these well-known cardiac func-
tional effects, more recently new evidences have
redefined the heart/thyroid liaison with the
introduction of new physiological and
pathophysiological concepts consisting of regen-
eration and redifferentiation processes and
protection.
Heart failure (HF) is an intriguing model of
chronic disease. First, it starts as a single-organ
disorder developing, in its progression, into a
systemic disease in which the dysfunction of
other organs plays a relevant clinical and prog-
nostic impact. Second, systemic pathways, con-
tinuously activated, play a central role in the
progression of the disease, switching their
effect from protective to harmful (FIGURE 1). In
this milieu of organ dysfunction and systemic
derangement, TH plays a fine from cardiovas-
cular to systemic tuning role, whose potential
is not completely understood, but that rises up
if we consider the negative impact of mild or
overt TH abnormalities in the molecular and
cellular processes as experimentally docu-
mented, and the negative clinical and
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prognostic impact in the clinical setting. This review focuses
on the new potential effects of TH on cell regeneration and
protection and the whole-body actions of TH in a context of
a systemic disease that is HF. Therefore, in the first part of
the review, some experiment-based TH actions regarding TH
effects on cellular regeneration, redifferentiation processes
and protection are discussed. In the second part, clinical
aspects of TH in HF are debated, in particular highlighting
the role of TH in a context of the co-morbidities occurring
in HF.
THs mechanisms of action: from old to new concepts
TH displays multiple actions at different levels in the
body, playing a crucial role in growth, differentiation and
metabolic homeostasis.
Triiodothyronine (T3) is commonly considered the bio-
logical active form of TH. It is mostly generated by
5’-monodeiodination of thyroxine (T4) in peripheral tissues
by type I and type II deiodinases. The heart is particularly
sensitive to the reduction in local T3 levels since the hor-
mone is fundamental to preserve both cardiac morphology
and performance through genomic and non-genomic effects.
The multiple genomic effects of TH on the heart are medi-
ated by TH-specific receptors (TRs), TRa (TRa1 and
TRa2) and TRb (TRb1 and TRb2) that bind as homo-
dimers or heterodimers to TH response elements (TREs) in
the promoter region of some genes. TRa1, the more com-
mon isoform in the heart, binds T3 with high affinity and is
considered a functional regulatory receptor, whereas TRa2
acts as a negative regulator since it binds TREs on DNA but
is deprived of the binding region for T3. For this peculiar
characteristic, TRa2 is believed to function as suppressor of
TRa1 transcription. Several important structural and func-
tional proteins are regulated by interaction of T3 receptor
complex with specific DNA sequences, either in physiologi-
cal or in pathological conditions. In a different way, the
non-genomic actions of TH do not require a TRE-mediated
gene transcription. The mechanisms of several of these non-
genomic actions of TH are now understood, at least in part,
and depend upon cellular signal transduction systems and
either novel cell surface receptors for TH, such as integrin
aVb3, [1,2], or extra-nuclear TRb [3] or TRa [4]. These
effects include several intracellular signaling pathways and
might involve the transport of ions across the plasma mem-
brane, glucose and amino acid transport, cytoskeleton and
mitochondrial function. Unlike the nuclear effectors, the
extra-nuclear effects may occur in a very short time and are
mediated by signal-transducing pathways [5].
In the last decade, beyond the classical effects of TH on
heart contractility and calcium handling, novel actions of TH
have emerged opening new perspectives on physiological and
therapeutic relevance of TH and their association to cardiac
regeneration/reparative process, stress response and cardiac
remodeling [6,7].
Cardiac growth & fetal gene program reactivation
In physiological conditions, TH-activated cardiac growth and
maturation require MHC gene regulation and, more specifi-
cally, a positive effect on the transcription of (MHC)a and a
negative action on (MHC)b gene expression. However, in the
course of cardiac remodeling following HF, several changes
aiming to restore the hemodynamic compromise are observed.
The reactivation of the fetal pattern of expression of contractile
proteins is one of the principal biochemical manifestations of
the switch to pathological hypertrophy, with a decreased
expression of (MHC)a and an overexpression of (MHC)b [8].
Evidence from neonatal cardiomyocyte cultures exposed to the
pro-growth factor phenylephrine (an a1-adrenergic agonist)
suggested a marked cell dedifferentiation with a myosin isoform
switch to a fetal pattern [9], and this response was associated to
a TRa1 redistribution from cytosol to nucleus. Furthermore,
TRa1 overexpression has been described in the development
of pathological hypertrophy after myocardial infarction in
rats, confirming its role as regulator of dedifferentiation/
redifferentiation in cardiac stress [10]. Administration of T3
converts TRa1 to the liganded form and this is associated to
cell redifferentiation and to the switch from the fetal to the
adult pattern of (MHC) genes, indicating that TH signaling
may promote the regeneration of damaged myocardium. To
further investigate the regulatory role of TH in pathological
cardiac growth and remodeling, the functions for specific miR-
NAs have been investigated [8]. In particular, miR-208 has
been described as an important cardiac-specific regulator of
(MHC)b expression and stress mediator for T3 signaling in the
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Figure 1. Heart failure is viewed as an allostatic overload
due to continuous activation of the different systemic
pathway working synergically to induce heart failure
progression. Green lines indicate the relationship among
the factors causing heart failure allostatic overload. Black lines
indicate the pathophysiological evolution of heart failure from an
organ to a systemic disease.
HF: Heart failure; RAAS: Renin-angiotensin-aldosterone system.
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failing heart. In the absence of miR-208, the expression of
(MHC)b is greatly reduced in adult mice in response to pres-
sure overload or hypothyroidism, indicating a common regula-
tory pathway involving miR-208 to regulate (MHC)b
transcription. It has been proposed that the (MHC)b gene may
respond to specific TR isoforms [8] and that co-regulators,
exerting positive and negative effects on transcription, may
enhance the repressive activity of the TR toward (MHC)b
expression. Therefore, it was hypothesized that co-regulators
may act on specific TR isoforms or, selectively, on a subset of
TR-dependent genes through interactions with promoter-
specific factors and that the regulatory role of miR-208 on car-
diac growth and gene expression might operate at this
level (FIGURE 2) [11,12].
Another interesting finding is that in hyperthyroid rats, the
angiotensin II receptor AT1R mediates the TH induction of
cardiac miR-208a and reduction of cardiac miR-208b levels.
The cardiac expression of miR-208a and miR-208b was associ-
ated with the expression of their corresponding myosin genes,
(MHC)a and (MHC)b, and, like miR-208a, also (MHC)a was
up-regulated by T3 whereas miR-208b (MHC)b was down-
regulated by the TH. These data strongly suggest that AT1R
might have an important regulatory role in cardiac muscle
strength and contractility, influencing the efficiency of the car-
diac function in hyperthyroidism [13].
Cardiac disease & TH-receptor axis impairment
TH affects cardiac growth and phenotype; however, the intra-
cellular mechanisms underlying this response remain poorly
understood since they are diverse and complex, cell type spe-
cific and involve multiple regulatory mechanisms.
Many evidences show that an impaired TH–TR axis is a
characteristic mark of the failing heart and is associated with
impaired cardiac function and increased mortality [14]. Even
though most of the effects of TH on cardiac function are
mediated by binding of the hormones to nuclear TRs, recent
studies supported the hypothesis that TRs could also mediate
T3 biological activities beyond TRE-mediated gene transcrip-
tion by a non-genomic action mediated by the TR cytosolic
counterpart [15,9]. In this matter, several studies focused on the
characterization of TRa1 isoform, which is most expressed in
the myocardium and is believed to play a crucial role in the
mediation of T3 effects on the recovery of cardiac function and
prevention of pathological hypertrophy after myocardial infarc-
tion. In neonatal rat, cardiomyocytes treated with phenyleph-
rine showed an increased nuclear TRa1 content associated
to cardiac pathologic growth only in the absence of T3 in the
culture medium, whereas a cardiac physiologic growth was
detected if T3 was present [16]. This finding strongly supports
the hypothesis that TRa1, depending on its liganded state,
may act as a molecular switch to convert pathologic to physio-
logic growth and that adrenergic system may play a role in
the mechanisms involved in the pathophysiology of cardiac
remodeling. The mechanisms involved in the TRa1 induction
after prolonged exposure of cardiomyocytes to phenylephrine
remain mostly unknown; however, most of them seem to be
mediated by ERK signaling pathway. It was observed that, in
the absence of T3, a redistribution of the TRa1 from nucleus
to cytosol was induced with a significant prevalence of
(MHC)b expression, leading to the fetal phenotype and patho-
logic growth. These findings are relevant in the context of HF
where a prolonged adrenergic stimulation occurs (FIGURE 3) [17].
Analogously, in another report, it was observed that TH
induced hypertrophy on rat neonatal cardiomyocytes as a direct
result of binding to the TRa1 isoform. It was shown that the
mechanism of TH and TRa1-specific hypertrophy involved
the p38, the arm of the mitogen-activated protein kinase
(MAPK) family most frequently associated with pathologic
hypertrophy. T3-induced p38 activity and myocyte growth was
due to the action of the TRa1 on the upstream kinase,
TAK1 (FIGURE 3) [9]. On the other hand, Kenessey et al. showed
that T3-physiologic cardiac growth is mediated by PI3K/Akt/
mTOR (mammalian target of rapamycin) signaling throughout
a direct interaction with cytosol-localized TRa1 [17]. Further-
more, protein–protein interactions between cytosolic TH recep-
tors and the p85 regulatory subunit of phosphatidylinositol
3-kinase (PI3K) have been recently reported in co-precipitation
studies in human endothelial cells, leading to the phosphoryla-
tion and activation of Akt and endothelial nitric oxidase syn-
thase [18]. The TR-mediated PI3K activation has also been
found in other cell types such as human fibroblasts [19] and
rat neonatal cardiomyocytes [17]. Interestingly, the activation
of PI3K and Akt appears to be a common pathway to various
cardioprotective mechanisms involving numerous peptide hor-
mones other than TH, including IGF-1, insulin, adrenomedul-
lin and estrogen [20,21].
All these data support the hypothesis that TRa1 isoform
and its signaling partners are likely to be involved in myocar-
dial growth and gene expression in diseased heart. This is of
clinical relevance since TH-TR axis may represent a new target
in possible therapeutic approach to HF.
miR-208 Co
TRE αMHC
TR
Nucleus
Cytosol
T3
TR
TRE βMHC
Figure 2. Schematic representation of nuclear T3–TR
interaction at TRE sequences, cofactor involvement and
MHCs and miR-208 regulation.
Co: Cofactors; T3: Triiodothyronine; TR: Thyroid receptor;
TRE: Thyroid hormone response elements; a and b MHC: Myosin
heavy chain.
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Integrin aVb3 mediation
Recent findings have demonstrated that TH non-genomic
action depends, at least in part, on interaction of the hormones
with specific cell surface or extra-nuclear receptors. In particu-
lar, the role of integrin aVb3 has been investigated [22]. Integ-
rin aVb3 is present in virtually all cells; it is a heterodimer
that interacts with several different proteins in the extracellular
matrix, being able to mediate a large number of cell signals.
TH ligand domain is at the so-called RGD (Arg-Gly-Asp) site
on the integrin and T4 affinity at this site is higher than
T3 [23]. The interaction of TH at the cell surface with integrin
aVb3 induces the activation of the serine-threonine kinase,
MAPK, ERK1/2. Also pro-angiogenic effects of TH either in
the heart (normal or failing) or in the peripheral vessels are
mediated by integrin aVb3 and promote arteriolar and capil-
lary growth [24]. Tetraiodothyroacetic acid (tetrac) is a deami-
nated analogue of T4 that blocks TH binding at the integrin
aVb3 receptor and inhibits the ability of TH analogues to acti-
vate MAPK pathway via this site. Interestingly, tetrac can also
inhibit the cellular effects of certain vascular endothelial growth
factors that contain an RGD sequence and act via integrin
aVb3 on endothelial cells [24].
HF: a paradigm model of systemic disease with thyroid
system as a new player
The systemic hypothesis of HF
In recent times, the classic hypothesis of HF interpreted as the
result of the unbalancing of cardio-hemodynamic system has
been greatly revisited and enriched by the new concept,
whereby HF is the inevitable consequence of a systemic multi-
factorial derangement at different levels in the whole body.
Therefore, on the basis of the original understanding, HF
progression was the result of increased cardiac loading condi-
tions and reduced cardiac contractility (hemodynamic hypothe-
sis) or the obvious consequence of a prolonged sodium
retention (cardiorenal hypothesis).
The neuroendocrine hypothesis gathers the activation of the
sympathetic autonomic nervous, renin–angiotensin–aldosterone
and natriuretic peptides atrial and brain natriuretic peptides
(ANP and BNP) systems that participate in the systemic
involvement of HF. Initially, their action is protective and
adaptive to hemodynamic changes induced by reduced cardiac
output. However, due to their continuous activation, their pro-
tective mechanisms become less effective first and then mal-
adaptive and dangerous for the entire body and heart,
contributing to progression of the disease [25]. At the cardiac
level, the result of the toxic action induced by continuous neu-
roendocrine activation is the ventricular remodeling process
that results in progressive enlargement and systo-diastolic dys-
function of the left ventricle. This is characterized by increased
myocardial mass, ventricular volume, change in ventricular
shape and interstitial growth. In particular, chamber dilatation
in progression to HF is largely due to myocyte lengthening
from series addition of new sarcomeres [26,27]. The prolonged
b- and angiotensin-receptor activation leads to an apoptotic
process [28,29], associated to left ventricular remodeling, progres-
sive dysfunction and thus HF progression [30].
Inflammatory system is also activated in HF initially with an
adaptive and protective function, producing several proteins in
the heart (free radical scavengers and heat shock proteins), con-
ferring resistance to myocardial hypoxic injury and providing a
stimulus for myocardial growth by promoting extracellular
matrix remodeling and cell proliferation [31,32] However, the
result of continuous activation of this system is dangerous for
the heart, with the induction of apoptosis in myocytes and
endothelial cells, worsening the left ventricular function [33].
The systemic involvement and derangement in HF, highlighted
by the above-mentioned hypothesis, has relevant clinical
impact, considering that the clinical condition of HF patients
is frequently characterized by several co-morbidities [34–36]. In
the study of Lee CS et al., three main ‘co-morbidity patterns’
were identified: the renal pattern with high incidence of renal
failure, complicated diabetes and fluid and electrolyte imbal-
ance; the neurovascular pattern characterized by prevalence of
cerebrovascular disease; the lifestyle pattern characterized by
uncomplicated diabetes, hypertension and pulmonary disorders.
All these patterns were associated with higher incidence of
death, longer hospital stay and greater health costs [37–40].
Low T3 syndrome, the more frequent TH alteration in HF
Subclinical hypothyroidism and low T3 syndrome are the more
frequent alterations of TH and metabolism [41]. In particular,
low T3 syndrome, which mimics hypothyroid state, sharing
similar cardiovascular and systemic alterations, is present in
about 30% of HF patients [42]. In the past, this was judged as
an adaptive mechanism inducing the reduction in metabolic
demand, and thus not suitable for medical treatment. However,
Cardiac injury
TRa1
supplement
PI3K/Akt/mTOR
Cardiac protection/
regeneration
Cardiac impairment
ERK/TAK1/p38
LowT3T3
Cytosol
Figure 3. Hypothesized cellular mechanisms driving to
cardiac protection, regeneration and impairment.
AKt: Serine/threonine-specific protein kinase; ERK: Extracellular
signal-regulated kinases; mTOR: Mammalian target of rapamycin;
p38: Mammalian p38 mitogen-activated protein kinases;
PI3K: Phosphatidylinositol 3-kinase; T3: Triidothyronine;
TAK1: TGFb (transforming growth factor b)-activated kinase1;
TR: Thyroid receptor.
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experimental evidences suggest the hypothesis of a direct
involvement of TH abnormalities, and thus of low
T3 syndrome, in the HF progression [39]. In the clinical setting,
low T3 syndrome has been associated with a worse prognosis
in HF patients, independent of conventional clinical and car-
diac variables. In particular, Kaplan–Meier survival curves of
patients with reduced left ventricular ejection fraction and total
T3 showed the highest mortality when compared with that of
patients with similar left ventricular ejection fraction but nor-
mal total T3. This finding indicates an independent prognostic
power of T3 in discriminating patients at high risk for death.
Further, the negative prognostic power is enhanced in those
patients with higher BNP concentration both in acute decom-
pensated and in chronic compensated HF [42,40]. In the Passino
study, both free T3 and BNP, together with NYHA classifica-
tion, were independent predictors of cardiac mortality among a
wide panel of clinical variables. Their additive prognostic
power was highlighted by the analysis of the survival curve of
those patients with combined high BNP/low free T3, who
showed the highest mortality rate and those with combined
low BNP/normal free T3. More recently, several studies enroll-
ing large cohort of patients showed that increasing thyroid
stimulating hormone (TSH) levels above normal were indepen-
dently associated with an increased risk of HF in elderly popu-
lation with known cardiovascular risk factors or previous
cardiovascular disease and in HF patients with clinical HF pro-
gression and increased mortality. Furthermore, the studies
showed that the prognostic impact was maintained, even after
adjusting for other known predictors of outcome [43–47]. How-
ever, in one article published in the same period of the above-
mentioned studies, TSH was weakly associated with cardiac
mortality and this association disappeared after adding proBNP
values in the statistical analysis [48]. These contrasting data
could be explained by the distribution of TSH values within
the population enrolled, if we consider that in the population
subclinical hypothyroidism is associated with an increased risk
of cardiovascular events and mortality in those with a TSH
concentration of 10 mIU/l or greater [49]. In fact, in the Chen
Study, the highest TSH quartile was associated with increased
mortality compared with those with the lowest mortality [50].
Moreover, it is important to emphasize that the accurate defini-
tion of the TH metabolism cannot disregard the assessment of
the two THs, T3 and T4, considering the high incidence of
low T3 syndrome in HF characterized by a reduction in serum
total and free T3 concentrations in the presence of normal lev-
els of T4 and TSH [51].
The vicious circle among thyroid, the comorbidities & the
systems activated in HF
TH abnormalities occur frequently in co-morbidities inde-
pendently from HF, worsening the clinical status and
prognosis (FIGURE 4). Therefore, although there are no relevant
data on the potential association among TH abnormalities,
HF co-morbidities and HF, it is conceivable that these asso-
ciations could result in a vicious cycle, leading to additive
and detrimental effect on clinical conditions and prognosis
of HF patients. In particular, in HF subjects with hypothy-
roidism, renal insufficiency was significantly worse than in
patients with normal thyroid function [52,53]. Similarly, in
hemodialysis patients, low T3 syndrome was strongly associ-
ated with cardiac death and TH replacement therapy attenu-
ated the rate of decline in renal function in chronic renal
failure patients with subclinical hypothyroidism [54,55].
Thus, alterations in the levels and function of TH could be
considered to be cardiorenal connectors as both renal failure
and HF progress with the development of non-thyroidal
illness [56].
In diabetic patients, the prevalence of thyroid dysfunction is
greater than in the general population and is associated with
higher prevalence of microalbuminuria, also in pre-diabetic
subjects [57,58]. In the cross-talk among human body systems,
the increased HbA1C in hypothyroid non-diabetic patients is
intriguing, suggesting that anemia may be the connecting
link [59]. In fact, anemia can be a non-diabetic cause of
increased HbA1C circulating levels. Furthermore, anemia is fre-
quently diagnosed in hypothyroid patients as a result of iron
deficiency or depressed erythrocyte production by bone marrow
affecting the erythrocyte life span.
Brain
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emotional fragility
Red blood cells
Anaemia
Heart
Systolic and diastolic
dysfunction
Pancreas
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complications
Kidney
Renal failure
Muscles
Arteries
Vasoconstriction
Weakness
Figure 4. Cardiovascular and systemic effect of
hypothyroidism.
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Despite a recent paper concluding that the relationship
between thyroid function and depression remains poorly
defined [60], it has been observed that in subjects with
major depression, a blunted TSH response to TRH stimula-
tion associated with increased concentration of reverse
T3 and decreased concentration of T3 can induce low
T3 syndrome [61,62]. Interestingly, Bunevicius et al. showed
that patients with coronary artery disease and depressive
symptoms had a higher prevalence of HF, higher NT-pro
BNP concentrations and lower T3 than patients with coro-
nary artery disease without depressive symptoms. Further
higher NT-pro BNP concentrations were inversely related to
lower total T3 and to higher reverse T3 serum levels [63].
Taken as whole, these results suggest that symptoms of
depression in patients with coronary artery disease are associ-
ated with thyroid axis and cardiac impairment.
The bidirectional cross-talk between TH and inflammatory
and neuroendocrine system can also influence HF progres-
sion. Experimental studies showed that TH modulates the
sympathetic and plasma renin–angiotensin–aldosterone sys-
tem activating natriuretic peptide transcription and synthesis.
In hypothyroid patients, sympathetic activity is enhanced,
contributing to vasoconstriction and down-regulation of
adrenoreceptors [64]. Cytokines, in particular tumor necrosis
factor and IL-1 and IL-6, have been implicated in the patho-
genesis of low-T3 syndrome in HF patients through reduced
peripheral conversion of T4 into T3 and by inhibiting
5’deiodinase activity [65]. It is noteworthy that in HF patients
with low T3 syndrome, T3 treatment induced blunting of
inflammatory and neuroendocrine activation, with a reduc-
tion in plasma levels of norepinephrine, NT-proBNP, aldo-
sterone levels and IL-6 along with improvement in cardiac
performance [66].
Implications of substitutive TH treatment in HF
TABLE 1 summarizes the studies in which short-term and long-
term TH replacement therapy has been applied in patients
with ischemic and non-ischemic HF [66–73] A beneficial effect
on cardiac function and performance and reduction in systemic
cardiovascular resistance was shown. Also TH treatment
induced the resetting of neuroendocrine system, with a signifi-
cant reduction of circulating levels of catecholamines, aldoste-
rone and NT-proBNP after T3 treatment. These effects can be
direct mediated by the reciprocal interference among TH and
Table 1. Criteria for diagnosis of polycystic ovary syndrome.
Patients (N) Study design LVEF (%) TH dose treatment Main findings Ref.
10 pts with non-ischemic
HF
Randomized (1:1)
placebo controlled
27 ± 8 T4 100 mg/d OS for 1
week
Improvement in cardiovascular
performance at rest, exercise
and dobutamine stress test
[6]
10 pts with non-ischemic
HF
Randomized (1:1)
placebo controlled
29 ± 6 T4 100 mg/d OS for 3
months
Improvement in cardiovascular
performance at rest, exercise
and dobutamine stress test
[68]
23 pts with ischemic and
non-ischemic HF
Uncontrolled 22 ± 1 T3 cumulative dose
0.15-2.7 mg/kg bolus +
continuous infusion
(6-12 h)
# SVR
" CO
[69]
10 pts with cardiogenic
shock
Uncontrolled Not
available
T4 20 mg/h bolus +
continuous infusion (36h)
" CI, PCWP and MAP [70]
6 pts with ischemic and
non-ischemic HF
Uncontrolled 24 ± 3 T3 initial dose
20 mg/m2bs/d
Continuous infusion (4 d)
# SVR
" CO and UO
[71]
20 pts with ischemic and
non-ischemic HF
Randomized (1:1)
placebo controlled
25 (18-32) T3 initial dose
20 mg/m2bs/d
Continuous infusion (3 d)
" LVSV,LVEDV
# NT-proBNP, Aldosterone and
Noradrenaline
[70]
86 pts with ischemic and
non-ischemic HF
Randomized (2:1)
placebo controlled
28 ± 6 DTPA twice daily 90 mg
increments (every 2 wks
to maximum 360 mg)
" CI
# SVR, lipoproteins and
cholesterol
[72]
163 pts with ischemic
and non-ischemic HF and
subclinical
hypothyroidism
Uncontrolled T4 dose necessary to
normlaize TSH
" Physical performance at
6minute walking test
[73]
CI: Cardiac index; CO: Cardiac output; DITPA: 3,5-Diiodothyropropionic acid; HF: Heart failure; LVEF: Left ventricular ejection fraction; LVEDV: Left ventricular end
diastolic volume; LVSV: Left ventricular stroke volume; MAP: Mean arterial pressure; NT-proBNP: N-terminal pro-Brain natriuretic peptide; PCWP: Pulmonary capillary
wedge pressure; T3: Triiodothyronine; T4: Thyroxine; SVR: Systemic vascular resistance; UO: Urinary output.
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sympathetic and neuroendocrine pathways, but also indirectly
mediated by the improvement of hemodynamics, as docu-
mented by increased left ventricular stroke volume. Deactiva-
tion of the neuroendocrine system is a crucial goal in the
therapeutic management of HF. The potential clinical relevance
of T3-induced neuroendocrine deactivation is clearly deducible
from a study showing highly beneficial effects of aldosterone
and adrenergic antagonists in terms of survival, rate of hospital-
ization, symptoms, cardiac remodeling and performance [74].
Regarding side effects, all the studies showed no occurrence of
major or minor side effects and good tolerance without the
increase in heart rate, when T3 or T4 were used. On the con-
trary, the study of Goldman, in which 3,5-diidrothyropropionic
acid, a TH analog, has been used, was interrupted prematurely
due to the occurrence of side effects consisting of weight loss,
increased heart rate, fatigue, suppression of TSH and also a
trend toward increased mortality. However, all the referred
signs and symptoms suggest an excess in DITPA administration
as the main cause of thyrotoxicosis. This highlights an impor-
tant endpoint of TH treatment that is to restore TH deficien-
cies and maintain levels of circulating TSH, T3 and T4 within
normal ranges [75]. Moreover, the restoration of normal TH
metabolism is also an endpoint of TH treatment of chronic
kidney disease. Several studies showed the potential benefits of
a delay in progression of disease and obtaining clinical and bio-
humoral improvements [56]. However, the absence of sufficient
data derived from multicentric and long-term prognostic stud-
ies and the uncertainty on timing and hormone administration
modalities (intravenous or orally) do not allow TH treatment
in HF patient at this moment.
Expert commentary
In the pathophysiology of chronic stress stimuli, HF should be
seen in a unique scenario of altered systemic homeostasis in
which heart dysfunction, peripheral organ dysfunction and
derangement of the neuroendocrine, immune and inflamma-
tory systems represent chronic stress stimuli, with continuous
activation of the stress response. This, in turn, predisposes to
allostatic load, defined by McEwan as ‘the cumulative strain on
the body produced by repeated ups and downs of physiologic
response, as well as by the elevated activity of physiologic sys-
tems under challenge and the changes in metabolism and the
impact of wear and tear on a number of organs and tissue’,
which ‘can predispose the organism to disease’. In other words,
allostatic load is the price the body pays for being continuously
forced to adapt to adverse physical and pathophysiological
situations. In the case of HF, this refers to the continuous
up-regulation that occurs when neuroendocrine and immuno-
inflammatory systems shift their effects from compensatory
to unfavorable and, finally, to toxic, inducing left ventricle
remodeling at the level of the heart and the high incidence of
co-morbidities as expression of systemic derangement. In this
milieu of systemic dyshomeostasis, TH system can be included
because of the following reasons:
• The relevant role in the cardiovascular and systemic homeo-
stasis regulation and maintenance;
• The new evidences on cardiac protection and regeneration;
• The fine tuning between TH, neuroendocrine and inflamma-
tory systems;
• The frequent alteration of TH metabolism, consisting, in
particular, of the appearance of low T3 syndrome;
• The experimental and clinical evidences of the dangerous
effect of mild alteration of TH metabolism on cardiac func-
tion, structure and morphology and on the other organs
affected by HF syndrome;
• The initial and encouraging therapeutic approach with
replacement TH therapy.
Five-year view
HF syndrome may be considered a stress-induced disease, mainly
triggered by complex and concatenate systemic dysfunctions.
Therefore, a multifactorial approach may be more suitable in
order to accurately identify patterns of disease progression, prog-
nostic risk stratification and innovative therapeutical approaches.
In this context, TH system can play a pivotal role, particularly in
light of the new evidences of TH effects on cardiac protection
and regeneration, systemic homeostatic effects, reversibility of
genomic, structural and functional abnormalities after restoring a
normal TH metabolic pattern. Original molecular actions of TH
have recently emerged, opening new perspectives on physiologi-
cal and therapeutic relevance of TH and their association to car-
diac regeneration/reparative process, stress response and cardiac
remodeling. In particular, the miRNA regulatory role and the
recently unveiled TH–TR axis potential in the regulation of car-
diac regeneration/reparative process are surprisingly innovative
and open new innovative therapeutic approaches. Thus, T3, T4
and TSH are currently sampled in the daily clinical practice to
define more accurately clinical and prognostic stratification of
HF patients. The next challange will be to ascertain the benefit of
TH replacement therapy in HF patients, taking into consider-
ation type of hormone to administer, T3 or T4, and dosage and
treatment schedule.
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Key issues
• Heart failure (HF) is an intriguing model of chronic disease, in which systemic pathways, continuously activated, play a central role in the
progression of the disease, switching their effect from protective to harmful.
• An impaired thyroid hormone (TH)–TH receptor axis is a characteristic mark of the failing heart. TRa1, depending on its liganded
state, may act as a molecular switch of cellular pathways regulating cardiac regeneration/reparative process, stress response and
cardiac remodeling.
• TH non-genomic action depends, at least in part, on interaction of the hormones with specific cell surface or extra-nuclear receptors.
Particularly, integrin aVb3 is present in virtually all cells and mediates a large number of cell signals.
• TH plays a fine cardiovascular and systemic homeostatic role, if we consider the negative impact of mild or overt TH abnormalities in the
molecular and cellular processes as experimentally documented, and the negative clinical and prognostic impact in the clinical setting.
• Several questions arising from the clinical scenario support the experimental evidences showing a critical role of TH in HF. These
questions include the incidence and prognostic weight of TH abnormalities in HF, the effects of TH abnormalities on the same organs
and systems altered in HF and the potential benefits of restoring a normal TH profile by medical replacement therapy.
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